Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Collaborating with FNIH on Alzheimer's Biomarkers

NEW YORK (GenomeWeb) – Caprion Biosciences said today it has entered a collaboration with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to measure protein biomarkers linked to early disease progression in Alzheimer's.

Under the collaboration, Caprion will use its ProteoCarta mass spec platform to measure the levels of five proteins in the cerebrospinal fluid of more than 200 subjects including patients with Alzheimer's disease, mild cognitive impairment, and healthy controls, with the goal of determining the ability of these proteins to track disease progression. Patients will be tracked over the course of three years or more.

The company will also measure an additional 140 CSF proteins that have been linked to Alzheimer's and other central nervous system diseases.

"This partnership with the FNIH is a great example of Caprion's ongoing commitment to identifying and validating biomarkers of CNS diseases," Martin LeBlanc, Caprion's CEO, said in a statement. "Our CNS ProteoCarta biomarker panel builds on Caprion's expertise in large targeted protein assays in multiple therapeutic areas including Alzheimer's, Parkinson's, and Huntington's diseases."

Project participants also include Genentech, Janssen, Lundbeck, Merck, Takeda, the University of Pennsylvania, and Yale School of Medicine.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.